Large advances in malaria mortality reduction in the early twentieth century were squandered ins ucceeding decades. Malaria currently kills around 2-3 million people each year. Malaria control technology such as insecticide-treated bednets and chemotherapy might significantly reduce mortality, but an effective malaria vaccine is also required. Malaria subunit vaccines are beingd eveloped using advances in vaccine technology and immunology. Malaria is being tested first for novel ways that might lead to viable vaccinations for other illnesses. We present recent advances in malaria vaccine development, including grounds for cautious optimism, the sort of vaccine that may reasonably be expected, and how the process could be accelerated. Although precise projections are impossible, a deployable, effective malaria vaccine is a realistic medium-to long-term aim provided adequate money is mobilized.